前列腺癌在组织病理学差异下的可见性:一项单中心多参数磁共振成像研究
本研究纳入2015年6月至2020年12月间58例有mpMRI和全mount标本的前列腺癌患者共112个临床显著癌灶,按PI-RADS v2.1评估,探讨不同组织病理学成分(筛状结构、导管内模式或无此二者)的癌灶在mpMRI上的可见性差异。结果显示三组不可见比例分别为21.42%、39.53%和42.8%(P=0.111),差异未达统计学显著,但筛状成分及无导管内/筛状成分的癌灶似乎更易表现为mpMRI不可见。
要点
- 临床显著前列腺癌灶中,导管内模式、筛状成分、无此二者分别占25%、38.05%、36.60%。
- 三组mpMRI不可见比例分别为21.42%、39.53%、42.8%,差异未达统计学显著(P=0.111)。
- 筛状成分及无导管内/筛状成分的癌灶似乎比导管内模式更易在mpMRI上不可见。
核心结论
- 尽管未达统计学显著,伴有筛状成分及无任何导管内或筛状成分的临床显著前列腺癌灶比导管内模式更可能表现为mpMRI不可见病灶。
研究设计与样本
- 单中心研究,纳入2015年6月至2020年12月间58例有mpMRI和全mount标本的前列腺癌患者共112个临床显著癌灶;采集方案遵循PI-RADS,两名观察者按PI-RADS v2.1指南在活检和根治性前列腺切除术前评估图像,分歧经联合会议解决;由泌尿生殖病理学家审阅全数字化mount标本,以Gleason评分7及以上(3+4及以上)和/或癌最大直径6 mm及以上和/或前列腺外侵犯定义为临床显著前列腺癌。
诊断标准与关键数值
- 临床显著前列腺癌定义为Gleason评分7及以上(3+4及以上)和/或癌最大直径6 mm及以上和/或前列腺外侵犯;mpMRI上PI-RADS评分<3的临床显著癌灶被认定为不可见病灶;导管内模式组28个癌灶中6个(21.42%)不可见,筛状成分组43个中17个(39.53%)不可见,无此二者组41个中18个(42.8%)不可见,P=0.111。
局限性
- 原文指出差异未达统计学显著。
- 原文结论提出需要进一步的多中心研究来精确阐明前列腺癌关于组织病理学组成的mpMRI特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate whether prostate cancer (PCa) lesions regarding histopathological composition exhibit different morphological features on multiparametric prostate MRI (mpMRI).
METHODS: We investigated men with PCa with available mpMRI and whole-mount specimens between June 2015 to December 2020.The acquisition protocol consistent with the Prostate Imaging Reporting and Data System (PI-RADS). Two observers evaluated the images following the PI-RADS v2.1. guideline before biopsy and radical prostatectomy. The discrepancies were resolved in a joint meeting. A genitourinary pathologist reviewed the whole-digitalized mount specimens, and the lesions with Gleason score of 7 and above (3 + 4 and above), and/or cancers with a maximum diameter of 6 mm and more, and/or extraprostatic extension were accepted as clinically significant PCa. The PI-RADS scores and the diameter of the clinically significant PCa on mpMRI concerning histopathological components (i.e., cribriform component, intraductal pattern, or without cribriform component or intraductal pattern) were investigated. The clinically significant PCa foci with PI-RADS score <3 was accepted as an invisible lesion on mpMRI.
RESULTS: In all, 58 men with a total of 112 clinically significant PCa foci, were enrolled in the study. The intraductal pattern, cribriform pattern, or none of these patterns were observed in 28/112 (25 %), 43/112 (38.05 %), and 41/112 (36.60 %) tumor foci. Six out of 28 (21.42 %), 17/43 (39.53 %), and 18/41 (42.8 %) foci with an intraductal pattern, cribriform component, or without any of them, respectively, were invisible on mpMRI (P = 0.111).
CONCLUSION: Though it was not reached a statistical significance, clinically significant PCa with the cribriform component and without any intraductal or cribriform component are more likely to manifests mpMRI invisible foci than the intraductal pattern. Further multi-center studies are warranted to precisely elucidate mpMRI features of PCa regarding histopathological composition.
引用
- Arslan A, Alis D, Tuna MB, et al. The visibility of prostate cancer concerning underlying histopathological variances: A single-center multiparametric magnetic resonance imaging study. Eur J Radiol. 2021. PMID: 34062471. doi:10.1016/j.ejrad.2021.109791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。